$1.15
+0.05 (+4.55%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where PLRX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional · 6 with posted results
Held by 10 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, MARSHALL WACE, LLP, MILLENNIUM MANAGEMENT LLC, +5 more) · FINRA short interest 5.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsNCT06270706Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: PLN-101095, PLN-101095, PLN-101095, PLN-101095, PLN-101095, PLN-101095, Pembrolizumab | Advanced or Metastatic Solid Tumor | 124 | Jun 2030 | ≤ 1,411 d | 2026-08-03 |
| Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary FibrosisNCT06097260results2026-08-05Change From Baseline in Forced Vital Capacity at Week 52Randomized · Quadruple-masked · TreatmentStudy Protocol: v2.22_EU ↗ · Study Protocol: v1.2 ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: DSMB recommendation | Drug: PLN-74809, Placebo | Idiopathic Pulmonary Fibrosis | 320 | 2025-04-04actual | — | 2026-08-05 |
| Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)NCT04480840results2026-01-23Number of Participants With Treatment Emergent Adverse EventsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: PLN-74809, Placebo | Primary Sclerosing Cholangitis | 121 | 2024-02-26actual | — | 2026-01-23 |
| Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)NCT05621252results2025-09-24Primary OutcomeRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: PLN-74809, Placebo | Idiopathic Pulmonary Fibrosis | 10 | 2023-12-27actual | — | 2025-12-05 |
| Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary FibrosisNCT04396756results2024-04-30Part A - Number of Participants With Treatment-Emergent Adverse EventsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: PLN-74809, Placebo | Idiopathic Pulmonary Fibrosis | 120 | 2023-02-01actual | — | 2024-06-03 |
| Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/NCT04072315results2023-12-12Number of Participants With a Predicted Effect on αVβ6 PET ( Positron Emission Tomography) in Lungs After Administration of Drug.Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: PLN-74809 · Radiation: Knottin tracer | Idiopathic Pulmonary Fibrosis | 9 | 2022-06-27actual | — | 2023-12-12 |
| Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19NCT04565249results2022-11-17Number of Participants With Treatment-related Adverse Events and Laboratory Abnormalities, Assessed by CTCAE V5.0Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Study halted and will not resume; participants are no longer being examined or receiving intervention | Drug: PLN-74809, Placebo | Acute Respiratory Distress Syndrome, SARS-CoV-2 | 6 | 2021-06-01actual | — | 2022-11-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19